title: Subcutaneous epoetin alfa as an adjunct to autologous blood donation before elective coronary artery bypass graft surgery.
abstract: Autologous blood (AB) donation can minimize exposure to allogeneic blood in patients scheduled for coronary artery bypass graft (CABG) surgery. During AB donation in this group of patients, minimization of the accompanying decrease in hemoglobin (Hb) levels is important to reduce the risk of provoking silent myocardial ischemia and/or arrhythmias. Recombinant human erythropoietin (rHuEPO) has been used to facilitate AB donation and minimize the accompanying decrease in Hb levels in patients scheduled for cardiac surgery. In 24 patients scheduled for CABG surgery, once-weekly subcutaneous (s.c.) administration of rHuEPO (epoetin alfa 400 IU/kg) plus oral iron supplementation for 4 weeks prior to surgery caused marked stimulation of erythropoiesis and significantly increased collection of autologous red blood cells (RBCs) compared with oral iron alone. Furthermore, epoetin alfa minimized the decrease in Hb levels associated with AB donation and significantly attenuated allogeneic blood requirements by facilitating the collection of 4 AB units prior to surgery. During AB donation, no changes in the incidence or severity of ischemic attacks or ST-segment changes were observed using electrocardiographic monitoring. Epoetin alfa was well tolerated. Once-weekly s.c. administration of epoetin alfa for 4 weeks therefore represents a practical means of facilitating AB donation by patients scheduled for CABG surgery.
authors.affiliation: Department of Anesthesiology, University of Graz, Austria.
authors.forename: H
authors.initials: H
authors.lastname: Gombotz
mesh_terms: D000740:Anemia / Q000517:prevention & control; D001804:Blood Transfusion, Autologous / Q000706:statistics & numerical data; D001026:Coronary Artery Bypass; D017558:Elective Surgical Procedures; D000068817:Epoetin Alfa; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage* / Q000494:pharmacology; D005296:Ferrous Compounds / Q000008:administration & dosage; D006438:Hemodilution; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D011292:Premedication; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D005296:Ferrous Compounds; D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; C020748:ferrous sulfate; D000068817:Epoetin Alfa